COVID-19: Federal & Non-Federal Funding Opportunities

To facilitate COVID-19 research projects, the OVPR has formed a team to identify funding opportunities and other programs to support this work. These opportunities will be shared with the research community on an ongoing basis.

Last updated on February 19, 2021

Jump to: Federal Sources  Non-Federal Sources

Federal

SPONSOR PROGRAM FUNDING DEADLINE
Department of Defense (DoD)

DARPA

 DARPA Broad Agency Announcements Not Limited Varies; 4/23/2020 for BTO
Department of Energy (DoE)

Argonne National Laboratory

 

 Expedited, Rapid Access Call for COVID-19 Research N/A Ongoing

Department of Health and Human Services (HHS)

ACL

 Innovations in Nutrition Programs and Services - Community Research - Forecasted Up to $300,000 ACL expects to post the opportunity around March 29, 2021

Department of Health and Human Services (HHS)

CDC

 Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States Vary with mechanism 7/16/2023

Department of Health and Human Services (HHS)

CDC

 Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health $750,000 4/4/2021

Department of Health and Human Services (HHS)

CDC

 Strengthening Public Health Research and Implementation Science (Operations Research) to Control and Eliminate Infectious Diseases Globally Up to $2,000,000 3/24/2021
Department of State (DoS) COVID-19 Small Grants Program Maximum award amount: $100,000 9/30/2020

Department of State (DoS)

E/GP

 Office of Global Partnerships: COVID-19 Private Sector Engagement & Partnership Fund Anticipated awards of $50,000 to $1,000,000 5/30/2021
National Institutes of Health (NIH) Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) Budgets not limited Application dates: 5/17/2021, 5/17/2022, 5/17/2023
National Institutes of Health (NIH)

AHRQ

 Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 Not specified None specified
National Institutes of Health (NIH)

NCATS

 Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need Vary with mechanism 7/10/2021
National Institutes of Health (NIH)

NCATS

 Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) Vary with mechanism 3/17/2021
National Institutes of Health (NIH)

NCI

 Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis N/A -- allows existing resources to be redirected For the duration of the present crisis
National Institutes of Health (NIH)

NCI

 Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control Funding up to $125,000 in direct costs for  maximum of one year. 3/31/2021
National Institutes of Health (NIH)

NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NIBIB, NCATS, NIAAA

 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional) Up to level of parent award Applications accepted on an ongoing basis through 3/25/2021

National Institutes of Health (NIH)

NCI, NHGRI, NCCIH, NINDS, ORIP, NIMHD, NIDCR, NIAID, NIAMS, NIEHS, NCATS, NIDCD, NICHD, NIDDK, NHLBI

 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project Up to $1,000,000 in direct costs for one year projects. 7/13/2020, 11/12/2020, 3/12/2021, and 7/12/2021
National Institutes of Health (NIH)

NHLBI

 Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) Up to level of parent award Applications accepted on a rolling basis through 5/15/2020
National Institutes of Health (NIH)

NHLBI

 Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)   7/6/2024
National Institutes of Health (NIH)

NIA		 Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19) Vary with mechanism 5/8/2023

National Institutes of Health (NIH)

NIAAA

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)

also

R21 and R03 companion FOAs

 Vary with mechanism 4/14/2021
National Institutes of Health (NIH)

NIAID		 Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Application budgets should not exceed the annual amount of the current parent award; projects should not exceed two years. Applications accepted on a rolling basis to 7/2/2021
National Institutes of Health (NIH)

NIAID

 Administrative Supplement Not Limited 2/6/2020 (applications accepted through 2/6/2021)
National Institutes of Health (NIH)

NIAID

 Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects No set limit on budgets 6/11/2021
National Institutes of Health (NIH)

NIAID, NIEHS

Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)

also

Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)

 For the U01: Up to $500,000 in direct costs per year, for a maximum of 5 years;
U19 budgets are limited to $1 million per year.		 6/4/2021
National Institutes of Health (NIH)

NIAID, NIGMS

 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) Not limited 2/6/2020 (applications accepted through 4/8/2020)
National Institutes of Health (NIH)

NIA, NIAAA, NICHD, NIDA, NIMH, NINDS, NINR, NIMHD, NCCIH

 Notice of Additional Due Date and Additional “Areas of Focus Especially of Interest” of PAR-19-373 and PAR-19-384, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)" Not limited Application dates: 6/8/2020 and 3/17/2021
National Institutes of Health (NIH)

NIMH, NIAA

 

 Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) Not limited 5/1/2021
National Institutes of Health (NIH)

NIAAA

 Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA Limited to no more than $100,000 direct costs per year for two, unless special permission is granted 4/15/2021
National Institutes of Health (NIH)

NIAID, NIA

 Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) Not limited 5/13/2020; 9/13/2020; and others
National Institutes of Health (NIH)

NIAID

 Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) Application budgets are not limited but need to reflect the actual needs of the proposed project. Applications accepted on a rolling basis through 7/8/2021
National Institutes of Health (NIH)

NIAID

 Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Up to level of parent award 3/25/2021
National Institutes of Health (NIH)

NIAID

 Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) $4,050,000 6/29/2020
National Institutes of Health (NIH)

NIAID

 Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed) $275,000 (direct costs) 9/9/2020
National Institutes of Health (NIH)

NIAID

 Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2 Not limited but prior approval required for applicants requesting $500,000 or more in direct costs in any year 9/1/2021
National Institutes of Health (NIH)

NIAID

 Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI) Standard R01 and R21 terms 1/7/2023

National Institutes of Health (NIH)

NIAMS

 Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases Vary with mechanism 11/18/2021

National Institutes of Health (NIH)

NICHD

 Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract Vary with mechanism 7/16/2023

National Institutes of Health (NIH)

NICHD

 Notice of Special Interest (NOSI) – Research on Rehabilitation Needs Associated with the COVID-19 Pandemic Vary with mechanism 5/8/2023
National Institutes of Health (NIH)

NIDA

 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus $100K direct costs/yr 3/19/2020 (applications accepted through 3/31/2021)
National Institutes of Health (NIH)

NIDA

 

 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus No more than $100,000 unless strongly justified 3/31/2021
National Institutes of Health (NIH)

NIDA

 Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection Vary with mechanism 9/7/2024
National Institutes of Health (NIH)

NIDA

 Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders Vary with mechanism 9/7/2024
National Institutes of Health (NIH)

NIDA

 Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 Vary with mechanism 9/7/2024
National Institutes of Health (NIH)

NIDA

 Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders Vary with mechanism 9/7/2024
National Institutes of Health (NIH)

NIDCD

 

 Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders Vary with mechanism 9/8/2022

National Institutes of Health (NIH)

NIDCR

 Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19) Standard R01 and R21 terms 5/8/2023
National Institutes of Health (NIH)

NIEHS

 Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) Not specified 5/4/2021
National Institutes of Health (NIH)

NIGMS

 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 Must reflect your needs 3/5/2020 (applications accepted through 2/5/2021)

National Institutes of Health (NIH)

NIMH, NCCIH, SGMRO, ODP, NIDCD, OBSSR, NEI, NIDA, NIA, NIAAA, NICHD, NCATS, ORWH, NIDCR, NINR, NIMHD

 Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional) Up to $750,000 direct costs per year, for 3 years 8/20/2020, 12/2/2020, 3/2/2021
National Institutes of Health (NIH)

NIMHD, NIA, NIMH

 Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities No more than $125,000 in direct costs 5/1/2021
National Institutes of Health (NIH)

NIMHD, NIA, NIDA, NCI

 Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) Budget not limited; projects up to 5 years Standard NIH application dates, first date is 10/5/2020
National Institutes of Health (NIH)

NIMH, NIAAA

 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus Not specified 4/15/2021

National Institutes of Health (NIH)

NIMHD, NIAMS, NIDA, NIMH, NLM, NCI

 Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities Standard R01 budget 5/8/2023
National Institutes of Health (NIH)

NINDS

 Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System Budgets limited to $200,000 direct costs except in rare circumstances Applications accepted on a rolling basis through 4/14/2021

National Institutes of Health (NIH)

NLM, NIEHS, NIAMS, NIDCR, OBSSR, NIGMS, NHLBI, NCI, NIAAA, NINR, NCATS, ORWH, NHGRI, FIC, NCCIH, NIMH, THRO, NIDA, NINDS, NEI, NIMHD, NIAID, NIA, FDA, NIBIB, NIDCD, NICHD, NIDDK

 Notice of Special Interest: Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional) Support for up to one year and a maximum direct cost of $100,000 3/5/2021
National Institutes of Health (NIH)

OBSSR, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, NICHD

 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences Limited to no more than $100,000 direct costs per year unless strongly justified Applications accepted on a rolling basis through 3/31/2021
National Institutes of Health (NIH)

OD

 Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiatives   First due dates expected to be in July
National Institutes of Health (NIH)

OD

 Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Required)   Expected deadlines, May 2021

National Institutes of Health (NIH)

OISE

 Dear Colleague Letter: Future of International Research Collaboration Post COVID-19   3/31/2021

National Science Foundation (NSF)

BIO, ENG

 Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels) Budgets not limited The relevant programs in BIO/MCB and ENG/CBET all accept proposals without deadline. Proposals are reviewed as they are received.

U.S. Department of Agriculture (USDA)

NIFA

 Agriculture and Food Research Initiative - Foundational and Applied Science Program Vary with grant type 7/29/2021
USG

PHEMCE

 CoronaWatch: COVID-19 MEETING REQUEST FOCUS N/A  

Non-Federal

SPONSOR PROGRAM FUNDING DEADLINE
COVID-19 Early Treatment Fund (CETF) COVID-19 Early Treatment Fund (CETF)   Continuous submission
COVID-19 HPC Consortium The COVID-19 High Performance Computing (HPC) Consortium Not specified None specified
Robert Wood Johnson Foundation Pioneering Ideas: Exploring the Future to Build a Culture of Health The average Pioneer grant in 2019 was $315,031. However, there is not an explicit range for budget requests. Grant periods are flexible, though generally range from 1 to 3 years. Open
Russell Sage Foundation Social, Political, Economic, and Psychological Consequences of the COVID-19 Pandemic   LOIs for grants in the current funding cycle are due by May 4, 2021

Questions About Research & COVID-19

Please contact the OVPR with your questions and feedback related to research during the COVID-19 pandemic.

Contact Us